Investigating the effects of DFMO and AMXT 1501 on brain tumor metabolism

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early phase I trial examines how the drugs eflornithine (DFMO) and AMXT 1501 affect the metabolism of diffuse or high-grade gliomas in patients. Participants will undergo surgical resection of their tumors, followed by treatment with DFMO and AMXT 1501, while their tumor's metabolic response is monitored through microdialysis. The study aims to assess the impact of polyamine depletion on tumor metabolism and the feasibility of using microdialysis for pharmacodynamic evaluations in glioma patients. Additionally, the pharmacokinetics and adverse effects of the drugs will be evaluated in the postoperative setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>= 18 years
* Clinical and radiographic evidence suggesting a diagnosis of a diffuse high grade glioma (HGG), or a prior diagnosis of a diffuse glioma
* Planned subtotal resection or biopsy due to tumor location, size, or other clinical indication deemed appropriate by the surgeon
* Provide written informed consent for the current study and the Neuro-Oncology biorepository for archiving of cerebrospinal fluid (CSF) and blood samples collected on this protocol. Willing to remain in the hospital at Mayo Clinic (Rochester, MN) for three days added to their standard post-operative stay to undergo longitudinal microdialysis
* Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L without transfusion within 7 days preceding the lab assessment (obtained =\< 14 days prior to registration)
* Platelet \>= 100 x 10\^9/L, without transfusion within 7 days preceding the lab assessment (obtained =\< 14 days prior to registration)
* Hemoglobin \>= 9 g/dL, without transfusion support within 7 days preceding the lab assessment (obtained =\< 14 days prior to registration)
* Activated partial thromboplastin time or partial thromboplastin time (aPTT or PTT) =\< 1.5 x upper limit of normal (ULN) (obtained =\< 14 days prior to registration)
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN (obtained =\< 14 days prior to registration)
* Total serum bilirubin =\< 1.5 x ULN (obtained =\< 14 days prior to registration)
* The patient is clinically euthyroid \[Thyroid Stimulating Hormone (TSH)\]
* Serum creatinine =\< 1.5 x ULN or creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with serum creatinine levels above 1.5 x ULN (obtained =\< 14 days prior to registration)
* Negative serum or urine pregnancy test is required for female subjects of childbearing age \< 14 days prior to registration

Exclusion Criteria:

* Inappropriate surgical candidates due to current or past medical history or uncontrolled concurrent illness which limits safety of or compliance to study proceedings
* Vulnerable populations: pregnant or nursing women, prisoners, mentally handicapped
* Unable to swallow tablets or who are at risk for impaired absorption of oral medication. NOTE: This includes but not limited to, refractory vomiting, gastric resection/bypass, and duodenal/jejunal resection
* Known hypersensitivity or allergy to DFMO or AMXT 1501
* Contraindication to MRI or administration of gadolinium

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Terence C. Burns, MD, PhD — Mayo Clinic in Rochester
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epidemiological Profile of IDH-Mutant Diffuse Gliomas Diagnosed in Brazil (2021)

  This study collects medical chart data to see how IDH-mutant diffuse glioma presented and was treated in Brazil in 2021.

  Recruiting Latin American Cooperative Oncology Group · Salvador, Estado de Bahia and 11 other locations · NCT07789678

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas

  This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07468136

• T2* MRI and blood tests to predict progression of malignant gliomas

  This trial tests whether T2* MRI scans and blood biomarkers can help predict how WHO grade IV malignant gliomas will change or come back in adults.

  Recruiting University of Iowa · Iowa City, Iowa · NCT07447531

• Proton versus photon radiation for adults with primary brain tumors

  This trial will test whether proton beam radiation causes fewer long-term side effects than standard photon (X-ray) radiation in adults aged 18–70 with primary brain tumors who are expected to live more than five years.

  Recruiting Tata Memorial Centre · Mumbai · NCT06831461

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.